Drugs / c-myb AS ODN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00780052 | Sep 2002 → Aug 2011 | hematopoietic and lymphoid cell neoplasm | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | c-myb AS ODN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00780052 ↗ |
| Modality | Antisense oligonucleotide | “Infusional C-myb Antisense Oligodeoxynucleotide in Advanced Hematological Malignancies” NCT00780052 ↗ |
| Route | Intravenous | “continuous intravenous infusion over 7 days” NCT00780052 ↗ |